Journal
JOURNAL OF THORACIC ONCOLOGY
Volume 11, Issue 7, Pages 946-963Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtho.2016.05.008
Keywords
Non-small cell lung cancer; EGFR mutation; Tyrosine kinase inhibitor; Therapy; Resistance; Brain metastases
Categories
Funding
- Celgene
- Eisai
- Pfizer
- Novartis
- National Comprehensive Cancer Network Foundation
- Genentech
- Clinigen
- AstraZeneca Canada
- Pfizer Canada
- Clovis
- Lilly
- Transgene
- Genentech/Roche
- Boehringer Ingelheim
- Chugai
- Ono
- Taiho
- Merck
- AstraZeneca
- Ariad
- Bayer HealthCare
- Biothera
- Clovis Oncology
- Genentech of Roche
- Guardant Health
- Inivata
- Janssen Diagnostics
- Peregrine Pharmaceuticals
- Synta Pharmaceuticals
- Teva Pharmaceuticals
- Astra Zeneca
- Bristol-Myers Squib
Ask authors/readers for more resources
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent actionable alterations in non-small cell lung cancer.(NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-the-art review of the contemporary issues in managing this unique subgroup of patients. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available